Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Adv Healthc Mater. 2019 Mar 18;8(9):e1800987. doi: 10.1002/adhm.201800987

Figure 2.

Figure 2.

rBTNL2-Ig treatment delays the onset and reduces the incidence of autoimmune diabetes. Female NOD mice were injected i.p. with rBTNL2-Ig (25 or 50 µg) or control Ig (25 µg) twice weekly from 4 to 16 weeks of age. The mice were monitored for blood glucose levels each week. Mice with blood glucose of greater than 250 mg/dL on two consecutive readings were considered diabetic. The percentages of onset of diabetes are plotted at 12, 16, 20, 24, 28 and 32 weeks of age. The data are pooled from 3 independent experiments with 4–6 mice per group.